益气化痰方治疗中晚期非小细胞肺癌疗效及对细胞免疫功能、肿瘤标志物影响  

Effect of Using Yiqi Huatan Decoction in the Treatment of Advanced Non-small Cell Lung Cancer and Its Influence on Cellular Immune Function and Tumor Markers

作　　者：甄倩楠 焦进[1] 房国涛 张淑哲[2] 杜博闻 韩笑 ZHEN Qiannan;JIAO Jin;FANG Guotao(Key Laboratory of Mechanism and Procedures of Hebei Province,Department of Oncology,the Affiliated Hospital of Hebei University,Baoding Hebei 071000,China;Department of Traditional Chinese Medicine,the Third Central Hospital of Baoding City,Baoding Hebei 071000,China)

机构地区：[1]河北省放化疗机制与规程研究重点实验室/河北大学附属医院肿瘤内科,河北保定071000 [2]保定市第三中心医院中医科,河北保定071000 [3]保定市儿童医院口腔科,河北保定071000

出　　处：《四川中医》2021年第10期90-93,共4页Journal of Sichuan of Traditional Chinese Medicine

基　　金：保定市科技计划项目(编号:2041ZF325,题目:发光水凝胶的构筑及其对谷胱甘肽特异性的检测);河北大学附属医院青年科研基金项目(编号:2019Q034),题目:利用二代测序探索EGFR阳性肺腺癌转移相关分子标志物的研究。

摘　　要：目的:观察中药益气化痰方治疗中晚期非小细胞肺癌(NSCLC)的临床疗效。方法:将92例中晚期NSCLC患者按照随机数字表法分为治疗组和对照组,每组46例,对照组接受GP化疗方案,治疗组在对照组治疗基础上予以中药益气化痰方口服,两组均治疗4个疗程。比较两组近期疗效,并比较两组治疗前后中医证候评分、外周血CD_(3)^(+)、CD_(4)^(+)含量、CD_(4)^(+)/CD_(8)^(+)比值,比较两组治疗前后血清谷胱甘肽转硫酶P1(GSTP1)、细胞角质抗原21-1(CYFRA21-1)、磷酸化细胞外信号调节激酶(p-ERK)水平;并对两组患者进行Kaplan-Meie生存分型。结果:治疗后治疗组总有效率高于对照组(P<0.05),第2疗程后各个节点治疗组中医证候评分均低于对照组(P<0.01);治疗后治疗组外周血CD_(3)^(+)、CD_(4)^(+)含量及CD_(3)^(+)/CD_(4)^(+)值均高于对照组(P<0.01),血清GSTP1、CYFRA21-1、p-ERK水平均低于对照组(P<0.01),差异均有统计学意义。治疗组和对照组中位生存时间分别为37个月和34个月,经Log-rank检验,差异无统计学意义(P>0.05)。结论:益气化痰方可早期改善中医证候评分,调节机体细胞免疫功能,降低血清肿瘤标志物含量,治疗中晚期NSCLC效果显著。Objective:To investigate the clinical efficacy of using Yiqi Huatan Decoction in the treatment of advanced non-small cell lung cancer(NSCLC).Methods:92 patients with advanced NSCLC were randomly divided into a treatment group and a controlled group,with 46 cases in each group.The controlled group received GP chemotherapy,while the treatment group were given Yiqi Huatan Decoction on the basis of the controlled group.Both groups were treated for 4 courses.The short-term effect of the two groups was compared,and the TCM syndrome score,peripheral blood CD(3)^(+),CD(4)^(+)content,CD(4)^(+)/CD(8)^(+)ratio were compared between the two groups before and after treatment,and the levels of serum glutathione thiotransferase P1(GSTP1),cytokeratin antigen 21~1(CYFRA21~1)and phosphorylated extracellular signal regulated kinase(p-ERK)levels were compared between the two groups before and after treatment;Kaplan-Meie survival classification was performed for the two groups.Results:The total effective rate of the treatment group was higher than that of the controlled group after treatment(P<0.05),the TCM syndrome scores of the treatment group were lower than those of the controlled group after the second course of treatment(P<0.01).The levels of CD(3)^(+),CD(4)^(+)and CD(3)^(+)/CD(4)^(+)of the treatment group were higher than those of the controlled group after treatment(P<0.01),and the levels of GSTP1,CYFRA21-1 and p-ERK of the treatment group were lower than those of the controlled group(P<0.01).The median survival time of the treatment group and the controlled group was 37 months and 34 months respectively,and the difference was not statistically significant by log rank test(P>0.05).Conclusion:Yiqi Huatan Decoction can improve TCM syndrome score,regulate cellular immune function,reduce serum tumor markers,and it has significant effect in the treatment of advanced NSCLC.

关 键 词：非小细胞肺癌 中药 益气化痰方 细胞免疫 谷胱甘肽转硫酶P1 细胞角质抗原21-1 磷酸化细胞外信号调节激酶 

分 类 号：R734.2[医药卫生—肿瘤]